CTX-110 is under clinical development by CRISPR Therapeutics and currently in Phase II for B-Cell Chronic Lymphocytic Leukemia. According to GlobalData, Phase II drugs for B-Cell Chronic Lymphocytic Leukemia have a 12% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CTX-110’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CTX-110 overview
CTX-110 (previously known as CTX-101) is under development for the treatment of B-cell acute lymphocytic leukemia and B-cell non-hodgkin lymphomas including DLBCL, transformed follicular lymphoma, Richter’s transformation of CLL and acute lymphoblastic leukemia. The drug candidate consists of genetically modified chimeric antigen receptor (CAR-T) cells that target tumor cells expressing B lymphocyte antigen CD19. It is administered by intravenous route. It is developed based on CRISPR’s gene-editing technology.
See Also:
CRISPR Therapeutics overview
CRISPR Therapeutics (CRISPR) is a gene editing company. It focuses on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a gene-editing technology that modifies, deletes, or corrects disease-causing abnormalities at its genetic sources. Its major development programs include ex vivo programs involving gene editing of hematopoietic cells; ex vivo programs in immuno-oncology; in vivo programs targeting the liver and additional in vivo programs targeting other organ systems including muscle and lung. It has research and development operations in Cambridge, Massachusetts, the US and business operations in London, the UK. CRISPR is headquartered in Zug, Switzerland.
For a complete picture of CTX-110’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
